Trial Profile
A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Ganaxolone (Primary)
- Indications Epilepsy
- Focus Proof of concept; Therapeutic Use
- Sponsors Marinus Pharmaceuticals
- 13 Aug 2022 Status changed from active, no longer recruiting to completed.
- 01 Jul 2019 Status changed to active, no longer recruiting.
- 01 Jul 2019 Planned End Date changed from 1 Jan 2019 to 1 Jun 2021.